Last SFr.1.44 CHF
Change Today +0.01 / 0.70%
Volume 769.3K
EVE On Other Exchanges
SIX Swiss Ex
As of 11:43 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

evolva holding sa (EVE) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - SFr.1.62
52 Week Low
08/6/14 - SFr.1.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EVOLVA HOLDING SA (EVE)

Related News

No related news articles were found.

evolva holding sa (EVE) Related Businessweek News

No Related Businessweek News Found

evolva holding sa (EVE) Details

Evolva Holding SA, a biosynthetic company, discovers and develops ingredients and processes for nutrition, health care, and wellness products in Switzerland and internationally. Its technologies are based on yeast that is used in the production of food and beverages. The company’s principal products include Resveratrol, a natural compound produced in grapes and other plants as a response against environmental stress factors; Stevia, a leafy green plant used as natural, zero-calorie, high-and intensity sweetener forms in beverages; Vanilla, a complex blend of flavour and fragrance compounds extracted from the seed pods of the vanilla orchid; Saffron, a spice for food coloring and flavoring, as well as for its aroma properties; and Pomecins that prevent mould and yeast growth. It also offers EV-077, a reversible antagonist of isoprostanes and prostanoids for diabetic complications; and EV-35, a bacterial type II topoisomerase inhibitor. Evolva Holding SA is based in Reinach, Switzerland.

108 Employees
Last Reported Date: 09/4/14

evolva holding sa (EVE) Top Compensated Officers

Co-Founder, Chief Executive Officer, Managing...
Total Annual Compensation: SFr.346.4K
Compensation as of Fiscal Year 2013.

evolva holding sa (EVE) Key Developments

Evolva Holding SA and Cargill to Collaborate on Second Family of Ingredients

Evolva Holding SA and Cargill have signed an agreement to co-develop a sustainable, customisable, and cost-effective fermentation production process for a second family of high-value food and beverage ingredients. This additional collaboration between the two companies is modelled on the first partnership signed in March 2013 to develop next-generation stevia ingredients (steviol glycosides). This second family of high-value ingredients is unrelated to stevia. In the initial phase of the new collaboration, Evolva expects to deploy 5 - 7 researchers. Evolva and Cargill will share costs.

Takasago International Corporation Signs Collaboration with Evolva Holding SA

Takasago International Corporation has announced the signing of a binding term sheet for a collaboration with Evolva Holding SA. The aim of the collaboration is to co-develop novel biosynthetic production routes for several undisclosed ingredients with broad applications in the flavours and fragrances industry. Takasago and Evolva will apply Evolva's fermentation technology platform to develop and optimise yeast strains for the sustainable and cost-effective production of the ingredients. Takasago will have primary responsibility for regulatory approvals and commercialisation while Evolva will have primary responsibility for R&D, scale-up and manufacturing. During the multi-year R&D period, Evolva employees will work on the project and Evolva will be entitled to milestone payments if certain project goals are achieved. The two parties will share equally the costs and the economic value derived from the manufacturing and commercialisation of final products. Based on current plans, the collaboration could result in commercially viable products within 3-5 years. The final agreement is expected to be signed in the first quarter of 2015.

Evolva Holding SA. Sells EV-035 Series to Emergent BioSolutions

Evolva Holding SA. announced that Emergent BioSolutions Inc. has acquired Evolva's anti-bacterial programme, the EV-035 series. The lead compound in the EV-035 series is the broad-spectrum antibiotic GC-072, which is being developed with US government biodefense funding. For Evolva, this transaction is worth up to USD 70.5 million plus royalties. GC-072 has shown efficacy in both in vitro and in vivo studies against a wide range of bacterial pathogens, most notably Burkholderia pseudomallei. This bacterium causes the disease melioidosis and is regarded as a potential bio-threat agent. The preclinical development of GC-072 is funded by the Defense Threat Reduction Agency of the U.S. Department of Defense. Evolva and Emergent are working closely with DTRA on the transfer of the funding contract to Emergent, and expect this process to be completed. Evolva will receive from Emergent an upfront payment of USD 1.5 million, an additional USD 4 million after the US government approves transfer of the GC-072 contract to Emergent, development milestone payments up to USD 65 million, and tiered royalties up to a maximum of 10% on product net sales generated from the EV-035 programme. This transaction completes Evolva's strategic shift of focus towards ingredients for health, wellness and nutrition.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVE:SW SFr.1.44 CHF +0.01

EVE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EVE.
View Industry Companies

Industry Analysis


Industry Average

Valuation EVE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 38.2x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOLVA HOLDING SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at